89bio, Inc. Files 8-K: Material Definitive Agreement

TL;DR

89bio signed a big deal, filing an 8-K today.

AI Summary

On September 17, 2025, 89bio, Inc. entered into a material definitive agreement. The company also reported other events and filed financial statements and exhibits. The specific details of the agreement and financial information were not disclosed in this filing.

Why It Matters

This filing indicates a significant new agreement for 89bio, Inc., which could impact its future operations and financial performance.

Risk Assessment

Risk Level: medium — The filing indicates a material definitive agreement, which could carry significant implications for the company, but the lack of specific details introduces uncertainty.

Key Players & Entities

• 89bio, Inc. (company) — Registrant
• September 17, 2025 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of incorporation
• 655 Montgomery Street, Suite 1500 (address) — Principal executive offices
• San Francisco, CA 94111 (address) — Principal executive offices
• (415) 432-9270 (phone_number) — Registrant's telephone number

FAQ

Key Financial Figures

• $0.001 — ich registered Common Stock, par value $0.001 per share ETNB The Nasdaq Global Ma
• $14.50 — mmon Stock "), at an offer price of (i) $14.50 per Share in cash (the " Closing Amount
• $6.00 — ayments of up to an aggregate amount of $6.00 per Share upon the achievement of speci
• $79,900,000 — ation fee of an amount in cash equal to $79,900,000. The Merger Agreement also provides tha
• $2.00 — ollowing specified time periods: (i) $2.00 per Share, upon the First Commercial Sa
• $1.50 — " Milestone 1 Outside Date "). (ii) $1.50 per Share, upon worldwide Net Sales (as
• $3,000,000,000 — fined in the CVR Agreement) of at least $3,000,000,000 of a CVR Product in a single calendar y
• $2.50 — " Milestone 2 Outside Date "). (iii) $2.50 per Share, upon worldwide Net Sales of
• $4,000,000,000 — e, upon worldwide Net Sales of at least $4,000,000,000 of a CVR Product in a single calendar y

Filing Documents

• d143212d8k.htm (8-K) — 57KB
• d143212dex21.htm (EX-2.1) — 688KB
• d143212dex101.htm (EX-10.1) — 55KB
• d143212dex991.htm (EX-99.1) — 20KB
• g143212dsp149.jpg (GRAPHIC) — 9KB
• 0001193125-25-206747.txt ( ) — 1140KB
• etnb-20250917.xsd (EX-101.SCH) — 3KB
• etnb-20250917_lab.xml (EX-101.LAB) — 18KB
• etnb-20250917_pre.xml (EX-101.PRE) — 11KB
• d143212d8k_htm.xml (XML) — 4KB

Forward-Looking Statements

Forward-Looking Statements Certain statements in this Current Report on Form 8-K may constitute "forward-looking statements" within the meaning of the federal securities laws, including, but not limited to, statements regarding the ability to complete and the timing of completion of the transactions contemplated by the Merger Agreement, including the parties' ability to satisfy the conditions to the consummation of the tender offer and the other conditions to the consummation of the subsequent merger set forth in the Merger Agreement, and the possibility of any termination of the Merger Agreement. Words such as "may," "might," "will," "objective," "intend," "should," "could," "can," "would," "expect," "believe," "design," "estimate," "predict," "potential," "anticipate," "goal," "opportunity," "develop," "plan" or the negative of these terms, and similar expressions, or statements regarding intent, belief, or current expectations, are forward looking statements. While 89bio believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties (including, without limitation, those set forth in 89bio's filings with the SEC), many of which are beyond 89bio's control and subject to change. Actual results could be materially different. Risks and uncertainties include: risks associated with the timing of the closing of the proposed transaction, including the risks that a condition to closing would not be satisfied within the expected timeframe or at all or that the closing of the proposed transaction will not occur; uncertainties as to how many of 89bio's stockholders will tender their shares in the offer; the possibility that a governmental entity may prohibit, delay or refuse to grant approval for

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. 89bio, Inc. Date: September 18, 2025 By: /s/ Rohan Palekar Name: Rohan Palekar Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR